BioCentury
ARTICLE | Clinical News

Indevus Phase II pain data

December 3, 2002 8:00 AM UTC

IDEV said its IP 751 (formerly CT-3) synthetic cannabinoid gave a significant reduction in neuropathic pain in a placebo-controlled Phase II study of 21 patients with chronic pain resulting from spina...